https://www.selleckchem.com/products/u18666a.html
17; 95% confidence interval (CI) 1.08-1.26; ALP adjusted HR, 1.12; 95% CI 1.04-1.21], cardiovascular mortality (TBIL adjusted HR, 1.16; 95% CI 1.02-1.31; ALP adjusted HR, 1.16; 95% CI 1.05-1.28), and HF hospitalization (TBIL adjusted HR, 1.22; 95% CI 1.12-1.33; ALP adjusted HR, 1.12; 95% CI 1.03-1.23). Conclusion Elevated serum cholestasis markers TBIL and ALP were significantly associated with a poor outcome in HFpEF patients without chronic hepatic diseases, while elevated ALT and AST were not.Purpose of the Review The main objective